Yusuke Nakamura to Epitopes
This is a "connection" page, showing publications Yusuke Nakamura has written about Epitopes.
Connection Strength
1.303
-
Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]. Oncoimmunology. 2020 11 11; 9(1):1838189.
Score: 0.183
-
Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer. J Immunother. 2018 May; 41(4):201-207.
Score: 0.154
-
Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. Anticancer Res. 2014 Aug; 34(8):4201-5.
Score: 0.119
-
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med. 2014 Apr 03; 12:84.
Score: 0.116
-
A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med. 2014 Mar 10; 12:63.
Score: 0.115
-
Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2). PLoS One. 2014; 9(1):e85267.
Score: 0.114
-
A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci. 2011 Apr; 102(4):697-705.
Score: 0.093
-
[A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2271-3.
Score: 0.080
-
Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene. 2005 Sep 15; 24(41):6201-12.
Score: 0.064
-
Analysis of single-nucleotide polymorphisms in Japanese rheumatoid arthritis patients shows additional susceptibility markers besides the classic shared epitope susceptibility sequences. Arthritis Rheum. 2004 Jan; 50(1):63-71.
Score: 0.057
-
Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine. Front Immunol. 2023; 14:1223331.
Score: 0.056
-
SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. J Hum Genet. 2020 Dec; 65(12):1075-1082.
Score: 0.045
-
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016 05; 166-167:48-58.
Score: 0.033
-
Contribution of a haplotype in the HLA region to anti-cyclic citrullinated peptide antibody positivity in rheumatoid arthritis, independently of HLA-DRB1. Arthritis Rheum. 2009 Dec; 60(12):3582-90.
Score: 0.021
-
Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res. 2008 Oct 15; 14(20):6487-95.
Score: 0.020
-
Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci. 2006 May; 97(5):411-9.
Score: 0.017
-
Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res. 2004 Dec 15; 10(24):8577-86.
Score: 0.015